undamentalytics Newsletter
Sign in

Xilio Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Xilio Therapeutics, Inc. had total assets of $155m, total liabilities of $119m and shareholders' equity of $35.3m. It held $138m in cash against $0 of debt: net cash of $138m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents55138136
Total current assets60145145
Total assets71155154
Accounts payable332
Deferred revenue (current)144023
Total current liabilities275634
Total debt000
Total liabilities5311982
Shareholders' equity183572
Net debt (negative = net cash)−55−138−136
Shares outstanding3m9m7m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: CUVL vs XLOABCL vs XLOCYTK vs XLO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Xilio Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Xilio Therapeutics, Inc.